Komori
Zeria Pharmaceutical (4559) · RiskAdded Uncertainty Related to Trade Policy and International Affairs

Surging Energy and Raw Material Prices, Higher Logistics Costs, and Yen Depreciation Risk

First written in FY2023. 2 of 4 entries say "Restated". Latest entry: FY2026.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY20262023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Rising Procurement Costs Driven by Component Raw Materials, Transportation Costs and Yen DepreciationA theme 44 companies write about · 44 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2019: 11 of 17 companies on the "Worse" side.

1 other company's latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 44 companies compared. The sentences above are computed from all 44.
Full recordFilings, disclosures and news, newest first
  1. FY2026Added Uncertainty Related to Trade Policy and International AffairsAnnual report

    「Meanwhile, uncertainty about the outlook continued amid inflation resulting from higher energy and raw material costs, foreign exchange fluctuations, developments surrounding U.S. trade policy, the situation in the Middle East and other persistently tense international conditions.」

    U.S. trade policy and the situation in the Middle East were added as specific sources of uncertainty to the existing risks related to surging energy and raw material prices, foreign exchange rates and international conditions.
  2. FY2025RestatedAnnual report

    「Meanwhile, uncertainty about the outlook continued amid inflation resulting from higher energy and raw material costs, foreign exchange fluctuations, trends in interest rates in Europe and the United States, and persistently tense international conditions.」

    An uncertain business environment resulting from energy and raw material prices, foreign exchange rates, interest rates and international conditions continued.
  3. FY2024RestatedAnnual report

    「Meanwhile, uncertainty about the outlook continued amid inflation resulting from higher energy and raw material costs, yen depreciation and increasingly tense international conditions.」

    Higher energy and raw material prices, yen depreciation and uncertainty surrounding international conditions continued to be identified as business-environment risks.
  4. FY2023First statedAnnual report

    「Although the economy is recovering from the impact of the spread of COVID-19, surging energy and raw material prices, rising logistics costs and the rapid depreciation of the yen are expected to have a significant impact on corporate earnings going forward.」

    Energy and raw material prices, logistics costs and rapid yen depreciation were identified for the first time as a standalone theme and as major business and financial risks affecting corporate earnings. Surging prices, rising costs and yen depreciation were described as conditions that had already occurred.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.